Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults

. Author manuscript; available in PMC: 2015 Aug 13.

Published in final edited form as: Cochrane Database Syst Rev. 2014 Aug 13;8:CD003256. doi: 10.1002/14651858.CD003256.pub2

Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV-infected adults (Olweny 2005) – RCT

Patient or population: HIV-infected adults with severe (T1) Kaposi's sarcoma

Settings: Zimbabwe

Intervention: oral etoposide

Comparison: ABV

Outcomes	Illustrative comparative risks^* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	ABV	Oral etoposide
Mortality	864 per 1000	933 per 1000 (846 to 1000)	RR 1.08 (0.98 to 1.19)	178 (1 study)	⊕⊕⊕◯ moderate¹

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

ABV: doxorubicin, bleomycin and vincristine; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

There were few events with wide confidence intervals.